HLB Pept Signs Exclusive Supply Agreement with India's Bioserve

HLB Pept, a company specializing in peptides, announced on August 5 that it has signed an exclusive supply agreement for peptide materials with Bioserve Biotechnologies, an Indian biotechnology company. HLB Pept aims to expand its exports to the global market.

Under the agreement, Bioserve will import high-quality peptide raw materials manufactured by HLB Pept and exclusively supply them for research purposes throughout India. This agreement is significant as it expands HLB Pept's peptide production technology, which is the only one in Korea to have obtained GMP certification, to the global market.

Bioserve is a subsidiary of Reprocell, a Japanese regenerative medicine company, and is recognized for its advanced technology in India, focusing on DNA synthesis and gene analysis services. Its clients include major universities, public research institutions, and biotechnology companies across India.

HLB Pept, which became part of the HLB Group in March, has recently begun to accelerate its entry into overseas markets. In May, the active pharmaceutical ingredient for enuresis treatment produced by HLB Pept, 'Desmopressin,' received approval as a finished product. Next year, an FDA inspection is expected for the US entry of 'Ganirelix,' an active pharmaceutical ingredient for infertility treatment.

Shim Kyungjae, CEO of HLB Pept, said, "Through the agreement with Bioserve, we will expand our sales into the highly promising Indian market," and added, "We expect to create strong synergy in the local market through collaboration with Bioserve, which has an extensive network in the Indian bio industry."

This content was produced with the assistance of AI translation services.